Stromal tumor of uncertain malignant potential (STUMP) of the prostate is a rare tumor with a variable and unpredictable clinical course. Many STUMPs are diagnosed incidentally and never progress, while others may invade locally and rapidly recur after surgical intervention, and yet others may lead to distant metastasis and death. A wide array of histologic patterns is encompassed by STUMP, and distinguishing these tumors from prostatic stromal sarcoma or other causes of stromal expansion often proves difficult. Owing to the rarity of this tumor, there is not yet a consensus on appropriate management. However, owing to the possibility of aggressive behavior, close management and consideration of definitive resection is warranted.

Rivaroxaban confounds lupus anticoagulant testing because the DRVVT is prolonged in these patients but it also corrects with excess phospholipid, mimicking a lupus anticoagulant. Patient medication review is critical to avoid false-positive findings and inappropriate diagnosis of antiphospholipid syndrome.